James Christensen

Overview

Best Publications

• Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

  Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  5280
  Citations

• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy

  3652
  Citations

• In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship

  Dirk B. Mendel;A. Douglas Laird;Xiaohua Xin;Sharianne G. Louie

  3008
  Citations

• Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

  John M.L. Ebos;Christina R. Lee;William Cruz-Munoz;Georg A. Bjarnason

  2126
  Citations

• Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

  Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  2055
  Citations

• Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

  Alexa B. Turke;Kreshnik Zejnullahu;Yi Long Wu;Youngchul Song

  1252
  Citations

• Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

  J. Jean Cui;Michelle Tran-Dubé;Hong Shen;Mitchell Nambu

  1188
  Citations

• The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients

  Jill Hallin;Lars D. Engstrom;Lauren Hargis;Andrew Calinisan

  993
  Citations

• Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

  James E. Butrynski;David R. D’Adamo;Jason L. Hornick;Paola Dal Cin

  925
  Citations

• c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

  James G. Christensen;Jon Burrows;Ravi Salgia

  919
  Citations

• An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

  Helen Y. Zou;Qiuhua Li;Joseph H. Lee;Maria E. Arango

  900
  Citations

• Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

  James G Christensen;Helen Y Zou;Maria E Arango;Qiuhua Li

  773
  Citations

• Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

  Gromoslaw A. Smolen;Raffaella Sordella;Beth Muir;Gayatry Mohapatra

  731
  Citations

• c-Met: Structure, functions and potential for therapeutic inhibition

  Patrick C. Ma;Gautam Maulik;Gautam Maulik;James Christensen;Ravi Salgia;Ravi Salgia

  708
  Citations

• A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

  Takaaki Sasaki;Jussi Koivunen;Atsuko Ogino;Masahiko Yanagita

  699
  Citations

• Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer

  Patrick C. Ma;Ramasamy Jagadeeswaran;Simha Jagadeesh;Maria S. Tretiakova

  670
  Citations

• A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo

  James G. Christensen;Randall Schreck;Jon Burrows;Poonam Kuruganti

  665
  Citations

• MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

  Mark Magdi Awad;Geoffrey Raymond Oxnard;David M Jackman;Daniel O. Savukoski

  643
  Citations

• Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

  Sai Hong Ignatius Ou;Eunice L. Kwak;Christina Siwak-Tapp;Joni Dy

  594
  Citations

• Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

  Ultan McDermott;A. John Iafrate;Nathanael S. Gray;Toshi Shioda

  505
  Citations